Analysis of Drug Resistance Characteristics of Mycobacterium Tuberculosis in Anhui Province, 2016-2022
Xundi Bao,Shuo Liang,Jun Li,Qian Ye,Dandan Wu,Shu Wang,Yue Li,Yunsheng Ding,Jie Liu
DOI: https://doi.org/10.2147/idr.s460080
2024-06-20
Infection and Drug Resistance
Abstract:Xundi Bao, 1 Shuo Liang, 1 Jun Li, 1 Qian Ye, 1 Dandan Wu, 1 Shu Wang, 2 Yue Li, 1 Yunsheng Ding, 1 Jie Liu 3 1 Clinical Laboratory, Anhui Provincial Chest Hospital (Provincial Institute of Tuberculosis Control), Hefei, Anhui, People's Republic of China; 2 Department of Science and Education, Anhui Provincial Chest Hospital (Provincial Institute of Tuberculosis Control), Hefei, Anhui, People's Republic of China; 3 Tuberculosis Control Institute, Anhui Provincial Chest Hospital (Provincial Institute of Tuberculosis Control), Hefei, Anhui, People's Republic of China Correspondence: Xundi Bao, Clinical laboratory, Anhui Provincial Chest Hospital (Provincial Institute of Tuberculosis Control), No. 397, Jixi Road, Shushan District, Hefei, Anhui, People's Republic of China, Tel +86-13866774716, Email Objective: To preliminarily assess the prevalence and control effect of tuberculosis and drug-resistant tuberculosis (TB) in Anhui province, and analyze the trends in the changing drug resistance spectrum of Mycobacterium tuberculosis (Mtb) isolated in Anhui province from 2016 to 2022. Methods: From 2016 to 2022, a total of 2336 culture-positive tuberculosis strains were collected from four drug resistance monitoring sites. Patient demographic information was collected and drug susceptibility testing was conducted. Results: Among the 2336 Mycobacterium tuberculosis complex strains, 1788 (76.54%) were from male patients and 548 (23.46%) were from female patients. The majority were of Han ethnicity, from rural areas, and employed in agriculture, with 12.54% (285/2273) having diabetes. A total of 1893 (81.04%) strains were sensitive to all six anti-TB drugs tested, and 443 (18.96%) strains were resistant to at least one or more anti-TB drugs. The drug resistance rate for patients undergoing initial treatment was 16.80% (348/2071), and 35.85% (95/265) for those receiving retreatment. Among the six anti-TB drugs, the resistance rates from highest to lowest were: INH (10.55%, 236/2336), SM (8.18%, 183/2336), OFX (6.53%, 146/2336), RFP (5.95%, 133/2336), EMB (2.37%, 53/2336), KM (1.97%, 44/2336). Significant differences were observed in MDR strains across different ages, types, with or without diabetes, and geographical sources (χ 2=14.895,76.534,6.032,5.109, all P< 0.05). Conclusion: The tuberculosis prevention and control measures have controlled the drug resistance rate of Mycobacterium tuberculosis to a certain extent. However, there are still statistical differences in drug resistance rates among TB patients with different categories, age groups, regions, and diabetic diseases. Early detection and prompt treatment of patients with drug-resistant TB remain critical to controlling the spread of this disease. Keywords: tuberculosis, mycobacterium, drug resistance, surveillance, population distribution, characteristic analysis Tuberculosis is considered the second deadliest communicable disease, primarily transmitted through respiratory droplets or aerosols. According to the 2023 WHO Tuberculosis Report, China holds the third-highest incidence of tuberculosis globally and ranks second in the prevalence of drug-resistant tuberculosis cases. 1 Subsequent to the implementation of the 13th Five-Year Plan for Tuberculosis Control and the Three-Year Tuberculosis Action Plan (2020–2022), there has been a significant reduction in the total number of tuberculosis cases in China. However, efforts to control drug-resistant tuberculosis have not yielded significant results. In particular, the treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) have deteriorated when compared to the pre-COVID-19 pandemic data, presenting challenges for the prevention and control of both tuberculosis and its drug-resistant forms in China. To dynamically monitor the prevalence of both tuberculosis and its drug-resistant strains in China, the country has undertaken both a national baseline survey and ongoing monitoring of tuberculosis drug resistance. Anhui province hosts four national tuberculosis drug resistance monitoring sites aimed at preliminarily assessing the prevalence and control effectiveness of tuberculosis and its drug-resistant variants. The following analysis is the results of drug resistance in four drug resistance monitoring sites in Anhui province from 2016 to 2022. 2 Tuberculosis strains that tested positive in culture were consistently collected from four drug-resistance monitoring sites between 2016 and 2022. These strains were initially identified as belonging to the Mycobacterium tuberculosis complex through the use of PNB and MPB64 antigen tests. Drug susceptibility testing was conducted empl -Abstract Truncated-
pharmacology & pharmacy,infectious diseases